Skip to main content
Erschienen in: Endocrine 3/2020

15.11.2019 | Original Article

Regulation of B cell homeostasis by Ptpn22 contributes to type 1 diabetes in NOD mice

verfasst von: Xiajie Shi, Feng Shao, Zhixia Li, Lin Kang, Junbin Liu, Stephan Kissler, Zhiguang Zhou, Lijing Jia, Peilin Zheng

Erschienen in: Endocrine | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A coding variant in PTPN22 (C1858T) is one of the most important genetic risk factors in type 1 diabetes (T1D). The role of the PTPN22 risk allele in B cells is still incompletely understood and has not been investigated directly in T1D. This study aimed to explore the role of PTPN22 in the homeostasis of B cells and its influence in T1D.

Methods

Wild-type (WT) and Ptpn22 inducible knockdown (KD) NOD mice were treated with 200 μg/ml doxycycline at the age of 10 weeks for 1–2 months. B cell compositions in the bone marrow, peritoneal cavity and spleen were examined. The pathogenicity of Ptpn22 KD B cells was explored by adoptive cell transfer.

Results

Ptpn22 silencing increased the frequency of recirculating mature B cells in the bone marrow, decreased the frequency of B-1a cells in the peritoneal cavity and suppressed the formation of marginal zone B cells and plasma cells in the spleen. Changes in the composition of the peripheral B cell compartment caused by altered cell proliferation while rates of apoptosis were not affected. Significantly, co-transfer of Ptpn22 KD B cells with NY8.3 diabetogenic T cells diminished the frequency of diabetes in recipient NOD.scid mice compared with co-transfer of WT B cells.

Conclusions

Our study constitutes the first functional study of Ptpn22 in B cells in NOD mice. Our findings suggest that Ptpn22 variation contributes to T1D by modifying the B cell compartment and support a gain-of-function for the PTPN22 disease variant.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat J.A. Todd, Etiology of type 1 diabetes. Immunity 32, 457–467 (2010)CrossRef J.A. Todd, Etiology of type 1 diabetes. Immunity 32, 457–467 (2010)CrossRef
2.
Zurück zum Zitat L.A. DiMeglio, C. Evans-Molina, R.A. Oram, Type 1 diabetes. Lancet 391, 2449–2462 (2018)CrossRef L.A. DiMeglio, C. Evans-Molina, R.A. Oram, Type 1 diabetes. Lancet 391, 2449–2462 (2018)CrossRef
3.
Zurück zum Zitat J. Diana, Y. Simoni, L. Furio, L. Beaudoin, B. Agerberth, F. Barrat, A. Lehuen, Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat. Med. 19, 65–73 (2012)CrossRef J. Diana, Y. Simoni, L. Furio, L. Beaudoin, B. Agerberth, F. Barrat, A. Lehuen, Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat. Med. 19, 65–73 (2012)CrossRef
4.
Zurück zum Zitat R.M. Hinman, J.C. Cambier, Role of B lymphocytes in the pathogenesis of type 1 diabetes. Curr. Diab. Rep. 14(11), 543 (2014)CrossRef R.M. Hinman, J.C. Cambier, Role of B lymphocytes in the pathogenesis of type 1 diabetes. Curr. Diab. Rep. 14(11), 543 (2014)CrossRef
5.
Zurück zum Zitat J.P. Palmer, C.M. Asplin, P. Clemons, K. Lyen, O. Tatpati, P.K. Raghu, T.L. Paquette, Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222, 1337–1339 (1983)CrossRef J.P. Palmer, C.M. Asplin, P. Clemons, K. Lyen, O. Tatpati, P.K. Raghu, T.L. Paquette, Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222, 1337–1339 (1983)CrossRef
6.
Zurück zum Zitat G. De Filippo, N. Pozzi, E. Cosentini, M. Cavalcanti, J.C. Carel, S. Tamasi, A. Franzese, C. Pignata, Increased CD5+CD19+ B lymphocytes at the onset of type 1 diabetes in children. Acta Diabetol. 34, 271–274 (1997)CrossRef G. De Filippo, N. Pozzi, E. Cosentini, M. Cavalcanti, J.C. Carel, S. Tamasi, A. Franzese, C. Pignata, Increased CD5+CD19+ B lymphocytes at the onset of type 1 diabetes in children. Acta Diabetol. 34, 271–274 (1997)CrossRef
7.
Zurück zum Zitat C. Deng, Y. Xiang, T. Tan, Z. Ren, C. Cao, G. Huang, L. Wen, Z. Zhou, Altered peripheral B-lymphocyte subsets in type 1 diabetes and latent autoimmune diabetes in adults. Diabetes Care 39, 434–440 (2016)CrossRef C. Deng, Y. Xiang, T. Tan, Z. Ren, C. Cao, G. Huang, L. Wen, Z. Zhou, Altered peripheral B-lymphocyte subsets in type 1 diabetes and latent autoimmune diabetes in adults. Diabetes Care 39, 434–440 (2016)CrossRef
8.
Zurück zum Zitat M.D. Pescovitz, C.J. Greenbaum, H. Krause-Steinrauf, D.J. Becker, S.E. Gitelman, R. Goland, P.A. Gottlieb, J.B. Marks, P.F. McGee, A.M. Moran, P. Raskin, H. Rodriguez, D.A. Schatz, D. Wherrett, D.M. Wilson, J.M. Lachin, J.S. Skyler, Type 1 diabetes Trialnet anti-CD20 Study Group, rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361, 2143–2152 (2009)CrossRef M.D. Pescovitz, C.J. Greenbaum, H. Krause-Steinrauf, D.J. Becker, S.E. Gitelman, R. Goland, P.A. Gottlieb, J.B. Marks, P.F. McGee, A.M. Moran, P. Raskin, H. Rodriguez, D.A. Schatz, D. Wherrett, D.M. Wilson, J.M. Lachin, J.S. Skyler, Type 1 diabetes Trialnet anti-CD20 Study Group, rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361, 2143–2152 (2009)CrossRef
9.
Zurück zum Zitat M.D. Pescovitz, C.J. Greenbaum, B. Bundy, D.J. Becker, S.E. Gitelman, R. Goland, P.A. Gottlieb, J.B. Marks, A. Moran, P. Raskin, H. Rodriguez, D.A. Schatz, D.K. Wherrett, D.M. Wilson, J.P. Krischer, J.S. Skyler, Type 1 diabetes TrialNet Anti-CD20 Study Group, B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care 37, 453–459 (2014)CrossRef M.D. Pescovitz, C.J. Greenbaum, B. Bundy, D.J. Becker, S.E. Gitelman, R. Goland, P.A. Gottlieb, J.B. Marks, A. Moran, P. Raskin, H. Rodriguez, D.A. Schatz, D.K. Wherrett, D.M. Wilson, J.P. Krischer, J.S. Skyler, Type 1 diabetes TrialNet Anti-CD20 Study Group, B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care 37, 453–459 (2014)CrossRef
10.
Zurück zum Zitat D.V. Serreze, H.D. Chapman, D.S. Varnum, M.S. Hanson, P.C. Reifsnyder, S.D. Richard, S.A. Fleming, E.H. Leiter, L.D. Shultz, B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new “speed congenic” stock of NOD.Ig mu null mice. J. Exp. Med. 184, 2049–2053 (1996)CrossRef D.V. Serreze, H.D. Chapman, D.S. Varnum, M.S. Hanson, P.C. Reifsnyder, S.D. Richard, S.A. Fleming, E.H. Leiter, L.D. Shultz, B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new “speed congenic” stock of NOD.Ig mu null mice. J. Exp. Med. 184, 2049–2053 (1996)CrossRef
11.
Zurück zum Zitat N. Bottini, L. Musumeci, A. Alonso, S. Rahmouni, K. Nika, M. Rostamkhani, J. MacMurray, G.F. Meloni, P. Lucarelli, M. Pellecchia, G.S. Eisenbarth, D. Comings, T. Mustelin, A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36, 337–338 (2004)CrossRef N. Bottini, L. Musumeci, A. Alonso, S. Rahmouni, K. Nika, M. Rostamkhani, J. MacMurray, G.F. Meloni, P. Lucarelli, M. Pellecchia, G.S. Eisenbarth, D. Comings, T. Mustelin, A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36, 337–338 (2004)CrossRef
12.
Zurück zum Zitat T. Vang, M. Congia, M.D. Macis, L. Musumeci, V. Orrú, P. Zavattari, K. Nika, L. Tautz, K. Taskén, F. Cucca, T. Mustelin, N. Bottini, Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37, 1317–1319 (2005)CrossRef T. Vang, M. Congia, M.D. Macis, L. Musumeci, V. Orrú, P. Zavattari, K. Nika, L. Tautz, K. Taskén, F. Cucca, T. Mustelin, N. Bottini, Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37, 1317–1319 (2005)CrossRef
13.
Zurück zum Zitat X. Dai, R.G. James, T. Habib, S. Singh, S. Jackson, S. Khim, R.T. Moon, D. Liggitt, A. Wolf-Yadlin, J.H. Buckner, D.J. Rawlings, A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J. Clin. Investig. 123, 2024–2036 (2013)CrossRef X. Dai, R.G. James, T. Habib, S. Singh, S. Jackson, S. Khim, R.T. Moon, D. Liggitt, A. Wolf-Yadlin, J.H. Buckner, D.J. Rawlings, A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J. Clin. Investig. 123, 2024–2036 (2013)CrossRef
14.
Zurück zum Zitat L. Menard, D. Saadoun, I. Isnardi, Y.S. Ng, G. Meyers, C. Massad, C. Price, C. Abraham, R. Motaghedi, J.H. Buckner, P.K. Gregersen, E. Meffre, The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Investig. 121, 3635–3644 (2011)CrossRef L. Menard, D. Saadoun, I. Isnardi, Y.S. Ng, G. Meyers, C. Massad, C. Price, C. Abraham, R. Motaghedi, J.H. Buckner, P.K. Gregersen, E. Meffre, The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Investig. 121, 3635–3644 (2011)CrossRef
15.
Zurück zum Zitat X. Lin, S. Pelletier, S. Gingras, S. Rigaud, C.J. Maine, K. Marquardt, Y.D. Dai, K. Sauer, A.R. Rodriguez, G. Martin, S. Kupriyanov, L. Jiang, L. Yu, D.R. Green, L.A. Sherman, CRISPR-Cas9-mediated modification of the NOD mouse genome with Ptpn22R619W mutation increases autoimmune diabetes. Diabetes 65, 2134–2138 (2016)CrossRef X. Lin, S. Pelletier, S. Gingras, S. Rigaud, C.J. Maine, K. Marquardt, Y.D. Dai, K. Sauer, A.R. Rodriguez, G. Martin, S. Kupriyanov, L. Jiang, L. Yu, D.R. Green, L.A. Sherman, CRISPR-Cas9-mediated modification of the NOD mouse genome with Ptpn22R619W mutation increases autoimmune diabetes. Diabetes 65, 2134–2138 (2016)CrossRef
16.
Zurück zum Zitat T. Habib, A. Funk, M. Rieck, A. Brahmandam, X. Dai, A.K. Panigrahi, E.T. Luning Prak, A. Meyer-Bahlburg, S. Sanda, C. Greenbaum, D.J. Rawlings, J.H. Buckner, Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J. Immunol. 188, 487–496 (2012)CrossRef T. Habib, A. Funk, M. Rieck, A. Brahmandam, X. Dai, A.K. Panigrahi, E.T. Luning Prak, A. Meyer-Bahlburg, S. Sanda, C. Greenbaum, D.J. Rawlings, J.H. Buckner, Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J. Immunol. 188, 487–496 (2012)CrossRef
17.
Zurück zum Zitat G. Metzler, X. Dai, C.D. Thouvenel, S. Khim, T. Habib, J.H. Buckner, D.J. Rawlings, The autoimmune risk variant PTPN22 C1858T alters B cell tolerance at discrete checkpoints and differentially shapes the naive repertoire. J. Immunol. 199, 2249–2260 (2017)CrossRef G. Metzler, X. Dai, C.D. Thouvenel, S. Khim, T. Habib, J.H. Buckner, D.J. Rawlings, The autoimmune risk variant PTPN22 C1858T alters B cell tolerance at discrete checkpoints and differentially shapes the naive repertoire. J. Immunol. 199, 2249–2260 (2017)CrossRef
18.
Zurück zum Zitat P. Zheng, S. Kissler, PTPN22 silencing in the NOD model indicates the type 1 diabetes-associated allele is not a loss-of-function variant. Diabetes 62, 896–904 (2013)CrossRef P. Zheng, S. Kissler, PTPN22 silencing in the NOD model indicates the type 1 diabetes-associated allele is not a loss-of-function variant. Diabetes 62, 896–904 (2013)CrossRef
19.
Zurück zum Zitat C. Schuster, K.D. Gerold, K. Schober, L. Probst, K. Boerner, M.J. Kim, A. Ruckdeschel, T. Serwold, S. Kissler, The autoimmunity-associated gene CLEC16A modulates thymic epithelial cell autophagy and alters T cell selection. Immunity 42, 942–952 (2015)CrossRef C. Schuster, K.D. Gerold, K. Schober, L. Probst, K. Boerner, M.J. Kim, A. Ruckdeschel, T. Serwold, S. Kissler, The autoimmunity-associated gene CLEC16A modulates thymic epithelial cell autophagy and alters T cell selection. Immunity 42, 942–952 (2015)CrossRef
20.
Zurück zum Zitat P. Schneider, H. Takatsuka, A. Wilson, F. Mackay, A. Tardivel, S. Lens, T.G. Cachero, D. Finke, F. Beermann, J. Tschopp, Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J. Exp. Med. 194, 1691–1697 (2001)CrossRef P. Schneider, H. Takatsuka, A. Wilson, F. Mackay, A. Tardivel, S. Lens, T.G. Cachero, D. Finke, F. Beermann, J. Tschopp, Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J. Exp. Med. 194, 1691–1697 (2001)CrossRef
21.
Zurück zum Zitat J.N. Schickel, M. Kuhny, A. Baldo, J.M. Bannock, C. Massad, H. Wang, N. Katz, T. Oe, L. Menard, P. Soulas-Sprauel, T. Strowig, R. Flavell, E. Meffre, PTPN22 inhibition resets defective human central B cell tolerance. Sci. Immunol. 1, f7153 (2016)CrossRef J.N. Schickel, M. Kuhny, A. Baldo, J.M. Bannock, C. Massad, H. Wang, N. Katz, T. Oe, L. Menard, P. Soulas-Sprauel, T. Strowig, R. Flavell, E. Meffre, PTPN22 inhibition resets defective human central B cell tolerance. Sci. Immunol. 1, f7153 (2016)CrossRef
22.
Zurück zum Zitat S.B. Hartley, J. Crosbie, R. Brink, A.B. Kantor, A. Basten, C.C. Goodnow, Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 353, 765–769 (1991)CrossRef S.B. Hartley, J. Crosbie, R. Brink, A.B. Kantor, A. Basten, C.C. Goodnow, Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 353, 765–769 (1991)CrossRef
23.
Zurück zum Zitat M.S. Anderson, J.A. Bluestone, The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 23, 447–485 (2005)CrossRef M.S. Anderson, J.A. Bluestone, The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 23, 447–485 (2005)CrossRef
24.
Zurück zum Zitat G.J. Tsay, M. Zouali, The interplay between innate-like B cells and other cell types in autoimmunity. Front Immunol. 9, 1064 (2018)CrossRef G.J. Tsay, M. Zouali, The interplay between innate-like B cells and other cell types in autoimmunity. Front Immunol. 9, 1064 (2018)CrossRef
25.
Zurück zum Zitat J.J. Kenny, A.M. Stall, D.G. Sieckmann et al. Receptor-mediated elimination of phosphocholine-specific B cells in x-linked immune-deficient mice. J. Immunol. 146, 2568–2577 (1991)PubMed J.J. Kenny, A.M. Stall, D.G. Sieckmann et al. Receptor-mediated elimination of phosphocholine-specific B cells in x-linked immune-deficient mice. J. Immunol. 146, 2568–2577 (1991)PubMed
26.
Zurück zum Zitat L. Mandik-Nayak, J. Racz, B.P. Sleckman, M.C. Lamers, F.D. Finkelman, L. Finch, D.L. Longo, Autoreactive marginal zone B cells are spontaneously activated but lymph node B cells require T cell help. J. Exp. Med. 203, 1985–1998 (2006)CrossRef L. Mandik-Nayak, J. Racz, B.P. Sleckman, M.C. Lamers, F.D. Finkelman, L. Finch, D.L. Longo, Autoreactive marginal zone B cells are spontaneously activated but lymph node B cells require T cell help. J. Exp. Med. 203, 1985–1998 (2006)CrossRef
27.
Zurück zum Zitat K. Attanavanich, J.F. Kearney, Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J. Immunol. 172, 803–811 (2004)CrossRef K. Attanavanich, J.F. Kearney, Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J. Immunol. 172, 803–811 (2004)CrossRef
28.
Zurück zum Zitat E. Marino, M. Batten, J. Groom, S. Walters, D. Liuwantara, F. Mackay, S.T. Grey, Marginal-zone B-cells of nonobese diabetic mice expand with diabetes onset, invade the pancreatic lymph nodes, and present autoantigen to diabetogenic T-cells. Diabetes 57, 395–404 (2008)CrossRef E. Marino, M. Batten, J. Groom, S. Walters, D. Liuwantara, F. Mackay, S.T. Grey, Marginal-zone B-cells of nonobese diabetic mice expand with diabetes onset, invade the pancreatic lymph nodes, and present autoantigen to diabetogenic T-cells. Diabetes 57, 395–404 (2008)CrossRef
29.
Zurück zum Zitat E. Marino, J.L. Richards, K.H. McLeod, D. Stanley, Y.A. Yap, J. Knight, C. McKenzie, J. Kranich, A.C. Oliveira, F.J. Rossello, B. Krishnamurthy, C.M. Nefzger, L. Macia, A. Thorburn, A.G. Baxter, G. Morahan, L.H. Wong, J.M. Polo, R.J. Moore, T.J. Lockett, J.M. Clarke, D.L. Topping, L.C. Harrison, C.R. Mackay, Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat. Immunol. 18, 552–562 (2017)CrossRef E. Marino, J.L. Richards, K.H. McLeod, D. Stanley, Y.A. Yap, J. Knight, C. McKenzie, J. Kranich, A.C. Oliveira, F.J. Rossello, B. Krishnamurthy, C.M. Nefzger, L. Macia, A. Thorburn, A.G. Baxter, G. Morahan, L.H. Wong, J.M. Polo, R.J. Moore, T.J. Lockett, J.M. Clarke, D.L. Topping, L.C. Harrison, C.R. Mackay, Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat. Immunol. 18, 552–562 (2017)CrossRef
30.
Zurück zum Zitat P. Zheng, Z. Li, Z. Zhou, Gut microbiome in type 1 diabetes: a comprehensive review. Diabetes Metabol. Res. Rev. 34, e3043 (2018)CrossRef P. Zheng, Z. Li, Z. Zhou, Gut microbiome in type 1 diabetes: a comprehensive review. Diabetes Metabol. Res. Rev. 34, e3043 (2018)CrossRef
31.
Zurück zum Zitat L.I. Pao, K.P. Lam, J.M. Henderson, J.L. Kutok, M. Alimzhanov, L. Nitschke, M.L. Thomas, B.G. Neel, K. Rajewsky, B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 27, 35–48 (2007)CrossRef L.I. Pao, K.P. Lam, J.M. Henderson, J.L. Kutok, M. Alimzhanov, L. Nitschke, M.L. Thomas, B.G. Neel, K. Rajewsky, B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 27, 35–48 (2007)CrossRef
32.
Zurück zum Zitat J. Corte-Real, N. Duarte, L. Tavares, C. Penha-Gonçalves, Innate stimulation of B1a cells enhances the autoreactive IgM repertoire in the NOD mouse: implications for type 1 diabetes. Diabetologia 55, 1761–1772 (2012)CrossRef J. Corte-Real, N. Duarte, L. Tavares, C. Penha-Gonçalves, Innate stimulation of B1a cells enhances the autoreactive IgM repertoire in the NOD mouse: implications for type 1 diabetes. Diabetologia 55, 1761–1772 (2012)CrossRef
33.
Zurück zum Zitat P.L. Kendall, E.J. Woodward, C. Hulbert, J.W. Thomas, Peritoneal B cells govern the outcome of diabetes in non-obese diabetic mice. Eur. J. Immunol. 34, 2387–2395 (2004)CrossRef P.L. Kendall, E.J. Woodward, C. Hulbert, J.W. Thomas, Peritoneal B cells govern the outcome of diabetes in non-obese diabetic mice. Eur. J. Immunol. 34, 2387–2395 (2004)CrossRef
34.
Zurück zum Zitat R.A. Smerdon, M. Peakman, M.J. Hussain et al. CD5+ B-cells at the onset of type I diabetes and in the prediabetic period. Diabetes Care 17, 657–664 (1994)CrossRef R.A. Smerdon, M. Peakman, M.J. Hussain et al. CD5+ B-cells at the onset of type I diabetes and in the prediabetic period. Diabetes Care 17, 657–664 (1994)CrossRef
35.
Zurück zum Zitat C. Hulbert, B. Riseili, M. Rojas, J.W. Thomas, B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J. Immunol. 167, 5535–5538 (2001)CrossRef C. Hulbert, B. Riseili, M. Rojas, J.W. Thomas, B cell specificity contributes to the outcome of diabetes in nonobese diabetic mice. J. Immunol. 167, 5535–5538 (2001)CrossRef
Metadaten
Titel
Regulation of B cell homeostasis by Ptpn22 contributes to type 1 diabetes in NOD mice
verfasst von
Xiajie Shi
Feng Shao
Zhixia Li
Lin Kang
Junbin Liu
Stephan Kissler
Zhiguang Zhou
Lijing Jia
Peilin Zheng
Publikationsdatum
15.11.2019
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-02120-7

Weitere Artikel der Ausgabe 3/2020

Endocrine 3/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.